A series of studies confirmed the importance of FAK/Src signaling in resistance to first-(erlotinib), second- (afatinib), and third-generation (osimertinib) EGFR TKIs; thus, with the current diagnosis and mono target therapies against MET, this signaling could be implicated in MET-TKI resistance with an emphasis in metastatic tumors because it activates the signaling pathways such as MET/FAK involved in polymerization and contraction of the actin cytoskeleton to cell migration, followed by intra-extravasation through invasion of basal membrane and metastasis. The gene discussed is PTK2; the disease is metastatic neoplasm.